Harald Herrmann, Sabine Cerny-Reiterer, Karoline V. Gleixner, Katharina Blatt, Susanne Herndlhofer, Werner Rabitsch, Eva Jäger, Gerlinde Mitterbauer-Hohendanner, Berthold Streubel, Edgar Selzer, Ilse Schwarzinger, Wolfgang R. Sperr, Peter Valent. CD34+/CD38− stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin. haematol [Internet]. 2012Jan.31 [cited 2024Nov.25];97(2):219-26. Available from: https://haematologica.org/article/view/6210